Literature DB >> 16119753

Antimicrobial responses of Yersinia enterocolitica isolates in comparison to other commonly encountered bacteria that causes diarrhoea.

B Andualem1, A Geyid.   

Abstract

OBJECTIVE: To determine antimicrobial susceptibility and resistance of Yersinia enterocolitica, Shigella, E. coli and Salmonella isolated strains from diarrhoeal out-patients.
DESIGN: A cross-sectional study.
SETTING: Ethiopian Health and Nutrition Research Institute (EHNRI) in Addis Ababa Ethiopia.
SUBJECTS: Fifty one strains of enteric pathogenic bacterial isolates from 205 diarrhoeal out-patient cases.
RESULTS: All fifty one strains of enteric pathogenic bacterial isolates were sensitive to nalidixic acid, norfloxacin, and polymyxin B and 46 strains were resistant to cephalothin. Sensitivity to gentamycin, nalidixic acid, norfloxacin and polymyxin B is greater than 90% for the tested strains, while resistance to cephalothin, ampicillin and tetracycline was greater than 50%. All strains of Yersinia enterocolitica were sensitive to carbenicillin, chloramphenicol, gentamycin, kanamycin, nalidixic acid, norfloxacin, polymyxin B, streptomycin, sulphadiazene and trimethoprim-sulphamethoxazole. All strains of Yersinia enterocolitica were resistant to ampicillin. All of the 12 strains of Shigella were sensitive to nalidixic acid, norfloxacin, polymyxin B, gentamycin and kanamycin. Ampicillin, carbenicillin, cephalothin, streptomycin sulphadiazene, tetracycline and trimethoprim-sulphamethoxazole were sensitive against <50% of Shigella isolates. Among the isolates, 91.7% were resistant against tetracycline, 50% against cephlothin, and 75% against each of ampicillin and streptomycin. Totally, ten different patterns of resistance were noted for Shigella spp. All strains of diarrhoeagenic E. coli were sensitive to gentamycin, kanamycin, nalidixic acid, norfloxacin and polymyxin B, while 90.9% of them were sensitive to chloramphenicol. Of all these isolates, 81.8% strains were resistant to cephalothin and 63.6% to sulphadiazene. All Salmonella isolates were sensitive to norfloxacin, polymyxin B and nalidixic acid while 21 (95.5%) of strains were sensitive to gentamycin and kanamycin. Resistance level of 86.4% was found against cephalothin, 36.4% for ampicillin and 27.0% to sulphadiazene and to both streptomycin and trimethoprim-sulphamethoxazole in 22.7% of these strains. Eleven different combinations of resistant patterns were observed for all the Salmonella strains.
CONCLUSION: Gentamycin, kanamycin, nalidixic acid, norfloxacin and polymyxin B can be effective in the treatment of diarrhoea due to the enteropathogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16119753     DOI: 10.4314/eamj.v82i5.9313

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  4 in total

1.  Epidemiological patterns and antimicrobial resistance of bacterial diarrhea among children in Nairobi City, Kenya.

Authors:  Mark Kilongosi Webale; Christine Wanjala; Bernard Guyah; Nathan Shaviya; Godwil O Munyekenye; Peter Lokamar Nyanga; Immaculate Nyaseba Marwa; Sammy Kagoiyo; Laura Nyawira Wangai; Sella K Webale; Kenny Kamau; Nicholas Kitungulu
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

2.  Prevalence and Antimicrobial Resistance in Salmonella and Shigella Species Isolated from Outpatients, Jimma University Specialized Hospital, Southwest Ethiopia.

Authors:  Tesfahun Lamboro; Tsige Ketema; Ketema Bacha
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-08-23       Impact factor: 2.471

3.  Prevalence of intestinal parasitic and bacterial pathogens in diarrhoeal and non-diarroeal human stools from Vhembe district, South Africa.

Authors:  A Samie; R L Guerrant; L Barrett; P O Bessong; E O Igumbor; C L Obi
Journal:  J Health Popul Nutr       Date:  2009-12       Impact factor: 2.000

Review 4.  Prevalence of human Salmonellosis in Ethiopia: a systematic review and meta-analysis.

Authors:  Getachew Tadesse
Journal:  BMC Infect Dis       Date:  2014-02-19       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.